Research Paper Volume 12, Issue 7 pp 5792—5811
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML
Figure 7. Overall survival and disease free survival according to TP53 mutations. (A) Overall survival in TP53 mutated compared to TP53 wild-type patients. (B) Disease free survival in TP53 mutated compared to TP53 wild-type patients. (C) Overall survival in isolated TP53 mutated patients compared to those with TP53 mutations and concomitant -5/5q- and/or -7/7q- chromosomal deletions. (D) Disease free survival in isolated TP53 mutated patients compared to those with TP53 mutations and concomitant -5/5q- and/or -7/7q- chromosomal deletions. (E) Overall survival in isolated TP53 mutated compared to TP53 wild-type patients. (F) Disease free survival in isolated TP53 mutated compared to TP53 wild-type patients. (G) Overall survival in patients with TP53 mutations and concomitant -5/5q- and/or -7/7q- chromosomal deletions compared to TP53 wild-type patients. (H) Disease free survival in patients with TP53 mutations and concomitant -5/5q- and/or -7/7q- chromosomal deletions compared to TP53 wild-type patients.